Find information on thousands of medical conditions and prescription drugs.

Pompe's disease

Glycogen storage disease type II (also called Pompe disease or infantile acid maltase deficiency) is a rare genetic disorder caused by a deficiency in the enzyme acid alpha-glucosidase (GAA), which is needed to break down glycogen, a stored form of sugar used for energy. It is the only glycogen storage disease with a defect in lysosomal metabolism, and was the first glycogen storage disease to be identified—in 1932. The build-up of glycogen causes progressive muscle weakness throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver and nervous system. Transmission is by autosomal recessive inheritance. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Arthritis
Arthritis
Bubonic plague
Hypokalemia
Pachydermoperiostosis
Pachygyria
Pacman syndrome
Paget's disease of bone
Paget's disease of the...
Palmoplantar Keratoderma
Pancreas divisum
Pancreatic cancer
Panhypopituitarism
Panic disorder
Panniculitis
Panophobia
Panthophobia
Papilledema
Paraganglioma
Paramyotonia congenita
Paraphilia
Paraplegia
Parapsoriasis
Parasitophobia
Parkinson's disease
Parkinson's disease
Parkinsonism
Paroxysmal nocturnal...
Patau syndrome
Patent ductus arteriosus
Pathophobia
Patterson...
Pediculosis
Pelizaeus-Merzbacher disease
Pelvic inflammatory disease
Pelvic lipomatosis
Pemphigus
Pemphigus
Pemphigus
Pendred syndrome
Periarteritis nodosa
Perinatal infections
Periodontal disease
Peripartum cardiomyopathy
Peripheral neuropathy
Peritonitis
Periventricular leukomalacia
Pernicious anemia
Perniosis
Persistent sexual arousal...
Pertussis
Pes planus
Peutz-Jeghers syndrome
Peyronie disease
Pfeiffer syndrome
Pharmacophobia
Phenylketonuria
Pheochromocytoma
Photosensitive epilepsy
Pica (disorder)
Pickardt syndrome
Pili multigemini
Pilonidal cyst
Pinta
PIRA
Pityriasis lichenoides...
Pityriasis lichenoides et...
Pityriasis rubra pilaris
Placental abruption
Pleural effusion
Pleurisy
Pleuritis
Plummer-Vinson syndrome
Pneumoconiosis
Pneumocystis jiroveci...
Pneumocystosis
Pneumonia, eosinophilic
Pneumothorax
POEMS syndrome
Poland syndrome
Poliomyelitis
Polyarteritis nodosa
Polyarthritis
Polychondritis
Polycystic kidney disease
Polycystic ovarian syndrome
Polycythemia vera
Polydactyly
Polymyalgia rheumatica
Polymyositis
Polyostotic fibrous...
Pompe's disease
Popliteal pterygium syndrome
Porencephaly
Porphyria
Porphyria cutanea tarda
Portal hypertension
Portal vein thrombosis
Post Polio syndrome
Post-traumatic stress...
Postural hypotension
Potophobia
Poxviridae disease
Prader-Willi syndrome
Precocious puberty
Preeclampsia
Premature aging
Premenstrual dysphoric...
Presbycusis
Primary biliary cirrhosis
Primary ciliary dyskinesia
Primary hyperparathyroidism
Primary lateral sclerosis
Primary progressive aphasia
Primary pulmonary...
Primary sclerosing...
Prinzmetal's variant angina
Proconvertin deficiency,...
Proctitis
Progeria
Progressive external...
Progressive multifocal...
Progressive supranuclear...
Prostatitis
Protein S deficiency
Protein-energy malnutrition
Proteus syndrome
Prune belly syndrome
Pseudocholinesterase...
Pseudogout
Pseudohermaphroditism
Pseudohypoparathyroidism
Pseudomyxoma peritonei
Pseudotumor cerebri
Pseudovaginal...
Pseudoxanthoma elasticum
Psittacosis
Psoriasis
Psychogenic polydipsia
Psychophysiologic Disorders
Pterygium
Ptosis
Pubic lice
Puerperal fever
Pulmonary alveolar...
Pulmonary hypertension
Pulmonary sequestration
Pulmonary valve stenosis
Pulmonic stenosis
Pure red cell aplasia
Purpura
Purpura, Schoenlein-Henoch
Purpura, thrombotic...
Pyelonephritis
Pyoderma gangrenosum
Pyomyositis
Pyrexiophobia
Pyrophobia
Pyropoikilocytosis
Pyrosis
Pyruvate kinase deficiency
Uveitis
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Children have a 1 in 4 chance of inheriting the disease when both parents carry the abnormal gene. It is estimated to occur in about 1 in 40,000 births.

Variants

Pompe disease has three forms defined by age of onset and progression of symptoms:

Infantile, or early onset, is noticed shortly after birth. Symptoms include severe lack of muscle tone, weakness, and enlarged liver and heart. Mental function is not affected. Development appears normal for the first weeks or months but slowly declines as the disease progresses. Swallowing may become difficult and the tongue may protrude and become enlarged. Most children die from respiratory or cardiac complications before 2 years of age.

Juvenile onset symptoms appear in early to late childhood and include progressive weakness of respiratory muscles in the trunk, diaphragm and lower limbs, as well as exercise intolerance. Intelligence is normal. Most patients do not live beyond the second or third decade of life.

Adult onset symptoms also involve generalized muscle weakness and wasting of respiratory muscles in the trunk, lower limbs, and diaphragm. Many patients report respiratory distress, headache at night or upon waking, diminished deep tendon reflexes, and proximal muscle weakness, such as difficulty in climbing stairs. Intellect is not affected. A small number of adult patients live without major symptoms or limitations

Treatment

Cardiac and respiratory complications are treated symptomatically. Physical and occupational therapy may be beneficial for some patients. Alterations in diet may provide temporary improvement but will not alter the course of the disease. Genetic counseling can provide families with information regarding risk in future pregnancies.

Prognosis

The prognosis for individuals with Pompe disease varies according to the onset and severity of symptoms. The disease is particularly lethal in infants and young children.

Read more at Wikipedia.org


[List your site here Free!]


Enzyme Replacement Resolves Fabry Disease - Brief Article
From Family Pratice News, 3/1/01 by Mitchel L. Zoler

PHILADELPHIA -- Enzyme replacement therapy has conquered Fabry disease, a rare, lysosomal storage disease.

In two independent reports at the annual meeting of the American Society of Human Genetics, researchers reported successfully resolving Fabry disease symptoms with an infusion of a normal, human enzyme once every 2 weeks.

The enzyme, [alpha]-galactosidase, is now being made by two competing U.S. pharmaceutical companies. Based on the results of the two separate studies reported at the meeting, both companies have submitted licensing applications to the Food and Drug Administration under the Orphan Drug law, and expect a ruling this year. About 2,500 patients in the United States have Fabry disease.

The pathophysiology of Fabry disease centers on the accumulation of glycolipids that cannot be metabolized, and, instead, become deposited in the vascular endothelium. This eventually leads to damage of the skin, heart, and kidneys.

The results from one of the studies reported at the meeting--a 58-patient, placebo-controlled trial--documented that after 20 weeks of enzyme replacement therapy, the stored glycolipid completely disappeared from the renal vasculature in 20 of 29 treated patients. In contrast, none of the 29 patients treated with placebo infusions had clearance of their blood vessels, reported Dr. Christine M. Eng of Baylor College of Medicine in Houston.

"What we expected was that enzyme replacement would stabilize the disease, but what we see is a dramatic reversal," noted Dr. Robert J. Desnick, chairman of the department of human genetics at Mount Sinai Medical Center in New York, and a collaborator on the study A similar reversal of pathology has also been seen with enzyme replacement used to treat another lysosomal storage disease, Gaucher's disease.

"There is a pipeline of treatments that will soon become available for a variety of rare, lysosomal storage diseases," such as Niemann-Pick disease and Pompe's disease, Dr. Desnick said at a news conference at the meeting. The ability to treat these diseases effectively will place a new emphasis on early diagnosis, so that treatment can begin before irreversible pathology and sequelae occur, he added.

Early diagnosis of Fabry disease is challenging, Dr. Eng noted. It usually manifests first as pain in the hands and feet with no discernible cause. This symptom can be particularly suggestive if it occurs in two or more brothers (Fabry disease is X-linked, and so occurs overwhelmingly in males, although cases in females are possible). But the diagnosis is usually missed in childhood because the disease is so rare and therefore not near the top of a differential diagnosis list, she said.

As patients become teenagers and young adults, the pain becomes more intense, and can be accompanied by fever, rash in the genital region, and ocular findings. Damage to the skin, heart, and liver usually doesn't appear until the late 20s.

The second study that was reported at the meeting was an uncontrolled treatment trial with 26 patients. After 6 months of infusions every 2 weeks, all of the the patients had reductions in pain and in the glycolipid deposits in their vascular linings, reported Dr. Raphael Schiffmann, chief of the clinical investigation section in the developmental and metabolic neurology branch of the National Institute of Neurological Disorders and Stroke in Bethesda, Md.

Although both studies exclusively enrolled young adults who were at least 16 years old, tests for future treatment in children may eventually occur.

In both studies, the enzyme infusion was well tolerated, with no evidence of an allergic reaction to the infused protein.

COPYRIGHT 2001 International Medical News Group
COPYRIGHT 2001 Gale Group

Return to Pompe's disease
Home Contact Resources Exchange Links ebay